These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12552862)

  • 21. Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry.
    Flarakos J; Luo W; Aman M; Svinarov D; Gerber N; Vouros P
    J Chromatogr A; 2004 Feb; 1026(1-2):175-83. PubMed ID: 14763744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.
    Cabovska B; Cox SL; Vinks AA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):497-504. PubMed ID: 17344104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.
    Lancelin F; Bourcier E; Le Masson V; Lemeille Y; Brovedani S; Paubel P; Piketty ML
    Ther Drug Monit; 2010 Dec; 32(6):757-61. PubMed ID: 21068648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study.
    Siva Selva Kumar M; Ramanathan M
    Biomed Chromatogr; 2016 Feb; 30(2):263-8. PubMed ID: 26129833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma risperidone concentrations during combined treatment with sertraline.
    Spina E; D'Arrigo C; Migliardi G; Morgante L; Zoccali R; Ancione M; Madia A
    Ther Drug Monit; 2004 Aug; 26(4):386-90. PubMed ID: 15257068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
    Mihara K; Kondo T; Yasui-Furukori N; Suzuki A; Ishida M; Ono S; Kubota T; Iga T; Takarada Y; de Vries R; Kaneko S
    Ther Drug Monit; 2003 Jun; 25(3):287-93. PubMed ID: 12766554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
    Spina E; Avenoso A; Facciolà G; Salemi M; Scordo MG; Ancione M; Madia AG; Perucca E
    Psychopharmacology (Berl); 2001 Jan; 153(2):238-43. PubMed ID: 11205425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic drug monitoring of risperidone and its active metabolite 9-hydroxyrisperidone in the treatment of schizophrenia].
    Baymeeva NV; Platova AI; Kaleda VG; Miroshnichenko II
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(3):24-28. PubMed ID: 31089091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
    Saito M; Yasui-Furukori N; Nakagami T; Furukori H; Kaneko S
    J Clin Psychopharmacol; 2005 Dec; 25(6):527-32. PubMed ID: 16282832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone.
    Titier K; Déridet E; Moore N
    Toxicol Appl Pharmacol; 2002 Apr; 180(2):145-9. PubMed ID: 11969382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone.
    Aravagiri M; Marder SR; Nuechterlein KH; Gitlin MJ
    Ther Drug Monit; 2003 Dec; 25(6):657-64. PubMed ID: 14639051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.
    Yoshimura R; Ueda N; Nakamura J
    Neuropsychobiology; 2001; 44(3):129-33. PubMed ID: 11586052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
    Gunes A; Spina E; Dahl ML; Scordo MG
    Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.
    Aravagiri M; Marder SR
    Psychopharmacology (Berl); 2002 Feb; 159(4):424-31. PubMed ID: 11823895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An overdose of risperidone.
    Springfield AC; Bodiford E
    J Anal Toxicol; 1996; 20(3):202-3. PubMed ID: 8735204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmortem femoral blood concentrations of risperidone.
    Linnet K; Johansen SS
    J Anal Toxicol; 2014; 38(1):57-60. PubMed ID: 24324228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate.
    Spina E; Avenoso A; Facciolà G; Salemi M; Scordo MG; Giacobello T; Madia AG; Perucca E
    Ther Drug Monit; 2000 Aug; 22(4):481-5. PubMed ID: 10942191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
    Calarge CA; Miller del D
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):163-9. PubMed ID: 21486167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.